

Summary of risk management plan for Pregabalin Medical Valley 25, 50, 75, 100, 150, 200, 225 and 300 mg hårda kapslar (pregabalin)

This is a summary of the risk management plan (RMP) for Pregabalin Medical Valley 25, 50, 75, 100, 150, 200, 225 and 300 mg hårda kapslar. The RMP details important risks of Pregabalin Medical Valley 25, 50, 75, 100, 150, 200, 225 and 300 mg hårda kapslar and how more information will be obtained about Pregabalin Medical Valley 25, 50, 75, 100, 150, 200, 225 and 300 mg hårda kapslar's risks and uncertainties (missing information).

Pregabalin Medical Valley 25, 50, 75, 100, 150, 200, 225 and 300 mg hårda kapslar's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Pregabalin Medical Valley 25, 50, 75, 100, 150, 200, 225 and 300 mg hårda kapslar should be used.

Important new concerns or changes to the current ones will be included in updates of Pregabalin Medical Valley 25, 50, 75, 100, 150, 200, 225 and 300 mg hårda kapslar's RMP.

I. The medicine and what it is used for

Pregabalin Medical Valley 25, 50, 75, 100, 150, 200, 225 and 300 mg hårda kapslar is authorised for the treatment of Neuropathic Pain, Epilepsy, and Generalised Anxiety Disorder (see SmPC for the full indication).

It contains pregabalin as the active substance and it is given by oral route.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Pregabalin Medical Valley 25, 50, 75, 100, 150, 200, 225 and 300 mg hårda kapslar, together with measures to minimise such risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific Information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

II.A. List of important risks and missing information

Important risks of Pregabalin Medical Valley 25, 50, 75, 100, 150, 200, 225 and 300 mg hårda kapslar are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Pregabalin Medical Valley 25, 50, 75, 100, 150, 200, 225 and 300 mg hårda kapslar. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

List of important risks and missing information	
Important identified risks	• Dizziness, somnolence, loss of consciousness, syncope and potential for accidental injury • Discontinuation events • Drug interactions (lorazepam, ethanol and CNS depressants) • Euphoria • Congestive heart failure • Vision-related events
Important potential risks	• Suicidality • Off-label use in paediatric patients
Missing information	None

II.B. Summary of important risks

The safety information in the Product Information is aligned to the reference medicinal product.

II.C. Post-authorisation development plan

II.C.1. Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Pregabalin Medical Valley 25, 50, 75, 100, 150, 200, 225 and 300 mg hårda kapslar.

II.C.2. Other Studies in post-authorisation development plan

There are no studies required for Pregabalin Medical Valley 25, 50, 75, 100, 150, 200, 225 and 300 mg hårda kapslar.